Enliven Therapeutics ELVN Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's accounts payable?
- Enliven Therapeutics (ELVN) reported accounts payable of $1.64M in Q1 2026.
- How has Enliven Therapeutics's accounts payable changed year-over-year?
- Enliven Therapeutics's accounts payable increased by 5.0% year-over-year, from $1.56M to $1.64M.
- What is the long-term trend for Enliven Therapeutics's accounts payable?
- Over 4 years (2021 to 2025), Enliven Therapeutics's accounts payable has grown at a -8.0% compound annual growth rate (CAGR), from $10.46M to $7.5M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.